- Home
- ATOS vs RPTX Comparison
ATOS vs RPTX Comparison
Compare ATOS & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- RPTX
- Stock Information
- Founded
- ATOS 2009
- RPTX 2016
- Country
- ATOS United States
- RPTX Canada
- Employees
- ATOS N/A
- RPTX N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- ATOS Health Care
- RPTX Health Care
- Exchange
- ATOS Nasdaq
- RPTX Nasdaq
- Market Cap
- ATOS 174.8M
- RPTX 152.4M
- IPO Year
- ATOS 2012
- RPTX 2020
- Fundamental
- Price
- ATOS $1.19
- RPTX $2.97
- Analyst Decision
- ATOS Strong Buy
- RPTX Strong Buy
- Analyst Count
- ATOS 3
- RPTX 1
- Target Price
- ATOS $6.75
- RPTX $10.00
- AVG Volume (30 Days)
- ATOS 738.2K
- RPTX 113.0K
- Earning Date
- ATOS 11-12-2024
- RPTX 11-07-2024
- Dividend Yield
- ATOS N/A
- RPTX N/A
- EPS Growth
- ATOS N/A
- RPTX N/A
- EPS
- ATOS N/A
- RPTX N/A
- Revenue
- ATOS N/A
- RPTX $66,524,000.00
- Revenue This Year
- ATOS N/A
- RPTX $13.36
- Revenue Next Year
- ATOS N/A
- RPTX N/A
- P/E Ratio
- ATOS N/A
- RPTX N/A
- Revenue Growth
- ATOS N/A
- RPTX 18.19
- 52 Week Low
- ATOS $0.70
- RPTX $2.71
- 52 Week High
- ATOS $2.31
- RPTX $8.49
- Technical
- Relative Strength Index (RSI)
- ATOS 31.91
- RPTX 39.57
- Support Level
- ATOS $1.26
- RPTX $2.81
- Resistance Level
- ATOS $1.66
- RPTX $4.05
- Average True Range (ATR)
- ATOS 0.09
- RPTX 0.27
- MACD
- ATOS -0.03
- RPTX -0.08
- Stochastic Oscillator
- ATOS 4.08
- RPTX 16.92
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.